-
Sector Analysis
South Korea Cards and Payments – Opportunities and Risks to 2027
South Korea Cards and Payments Market Report Overview The annual value of card transactions in the South Korea cards and payments market was $991.2 billion in 2023 and will grow at a CAGR of more than 7% during 2023-2027. South Korea’s cards and payments industry is well-developed. A strong banked population, high financial awareness, banks incentivizing customers through a range of benefits, and government support to boost cashless payment methods have driven payment card adoption in the country. South Korea...
-
Product Insights
Dept des Landes – Tosse Tourist Golf Mixed-Use Complex – Nouvelle-Aquitaine
Equip yourself with the essential tools needed to make informed and profitable decisions with our Dept des Landes - Tosse Tourist Golf Mixed-Use Complex - Nouvelle-Aquitaine report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Sector Analysis
South Korea Cards and Payments – Opportunities and Risks to 2024
GlobalData’s 'South Korea Cards and Payments - Opportunities and Risks to 2024' report provides detailed analysis of market trends in the Korean cards and payments industry. It provides values and volumes for a number of key performance indicators in the industry, including cash, cards, credit transfers, direct debits, and cheques during the review-period (2016-20e). The report also analyzes various payment card markets operating in the industry, and provides detailed information on the number of cards in circulation, transaction values and...
-
Sector Analysis
Allergic Rhinitis Immunotherapy – Opportunity Analysis and Forecasts to 2028
Allergic rhinitis (AR) is a common, IgE-mediated inflammatory disease in which an individual reacts to an otherwise innocuous inhaled substance in the environment with one or more of the following symptoms: rhinorrhea, sneezing, nasal congestion, and pruritus of the eyes, nose, and palate. Based on epidemiological analysis by GlobalData, in 2018 there were over 70.5M 12-month diagnosed prevalent cases of AR among adults and adolescents throughout the seven major pharmaceutical markets (7MM) covered in this report, the US, 5EU (France,...